Trial Profile
A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Telisotuzumab (Primary) ; Capecitabine; Cetuximab; Docetaxel; Erlotinib; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Abbott Laboratories; AbbVie
- 06 Jun 2017 Status changed from active, no longer recruiting to completed.
- 20 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 29 Jun 2017.
- 05 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.